UCB SA Company Description

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.

The company’s primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome.

It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.

In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet/Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis.

Further, it develops doxecitine/doxribtimine for TK2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer’s disease; UCB0222 for the treatment of Parkinson’s disease; and UCB9741 and UCB1381 for atopic dermatitis.

Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

UCB SA

Country	Belgium
Founded	1925
Industry	Biological Products, Except Diagnostic Substances
Employees	9,378
CEO	Jean-Christophe Tellier

Contact Details

Address: Allée de la Recherche, 60 Brussels, 1070 Belgium
Phone	32 2 559 99 99
Website	ucb.com

Stock Details

Ticker Symbol	UCB
Exchange	Vienna Stock Exchange
Fiscal Year	January - December
Reporting Currency	EUR
SIC Code	2836

Key Executives

Name	Position
Jean-Christophe Tellier	Chief Executive Officer
Sandrine Dufour	Chief Financial Officer
Antje Witte	Head of Investor Relations